Sodium Picosulfate

CHEMBL1697768 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
481.4 g/mol
LogP
Phase
4

Sodium picosulfate is a stimulant laxative prodrug that is hydrolyzed by colonic bacteria to the active diphenol, which stimulates intestinal mucosa to increase peristalsis and fluid secretion, used for bowel preparation before colonoscopy and for the treatment of chronic constipation and inflammatory bowel disease. Unlike many osmotic laxatives, it acts locally in the colon and has minimal systemic absorption. It is commonly used in split-dose bowel preparation regimens in combination with magnesium citrate.

分子量

481.4000 g/mol

TPSA

163.00 Ų

治疗领域

作用机制

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=S(=O)([O-])Oc1ccc(C(c2ccc(OS(=O)(=O)[O-])cc2)c2ccccn2)cc1.[Na+].[Na+]

InChI

InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2

Molecular Formula

C18H13NNa2O8S2

HBD / HBA

- / 9

可旋转键数

5

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Sodium picosulfate is a stimulant laxative prodrug that is hydrolyzed by colonic bacteria to the active diphenol, which stimulates intestinal mucosa to increase peristalsis and fluid secretion, used for bowel preparation before colonoscopy and for the treatment of chronic constipation and inflammatory bowel disease. Unlike many osmotic laxatives, it acts locally in the colon and has minimal systemic absorption. It is commonly used in split-dose bowel preparation regimens in combination with magnesium citrate.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Sodium Picosulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1697768. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 68654. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.